Evidence map›Paper›PMID 26335183›Full record

ArticleOncotarget2015

Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.

Rayan S Moussa, Zaklina Kovacevic, Des R Richardson

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rayan S MoussaMolecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, 2006, Australia.
Zaklina KovacevicMolecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, 2006, Australia.
Des R RichardsonMolecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, 2006, Australia.
Robert Bosch (Australia) · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chelators such as 2-hydroxy-1-napthylaldehyde isonicotinoyl hydrazone (311) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) target tumor cell iron pools and inhibit proliferation. These agents also modulate multiple targets, one of which is the cyclin-dependent kinase inhibitor, p21. Hence, this investigation examined the mechanism of action of these compounds in targeting p21. All the chelators up-regulated p21 mRNA in the five tumor cell-types assessed. In contrast, examining their effect on total p21 protein levels, these agents induced either: (1) down-regulation in MCF-7 cells; (2) up-regulation in SK-MEL-28 and CFPAC-1 cells; or (3) had no effect in LNCaP and SK-N-MC cells. The nuclear localization of p21 was also differentially affected by the ligands depending upon the cell-type, with it being decreased in MCF-7 cells, but increased in SK-MEL-28 and CFPAC-1 cells. Further studies assessing the mechanisms responsible for these effects demonstrated that p21 expression was not correlated with p53 status, suggesting a p53-independent mechanism. Considering this, we examined proteins that modulate p21 independently of p53, namely NDRG1, MDM2 and ΔNp63. These studies demonstrated that a dominant negative MDM2 isoform (p75(MDM2)) closely resembled p21 expression in response to chelation in three cell lines. These data suggest MDM2 may be involved in the regulation of p21 by chelators.

Indexed as

Blotting, WesternCell Cycle ProteinsCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21Gene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsIron Chelating AgentsIsoniazidMCF-7 CellsMicroscopy, FluorescenceMolecular StructureNeoplasmsN-myc Downstream-Regulated Gene 1 ProteinProto-Oncogene Proteins c-mdm22-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazoneCDKN1A protein, humanCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p21di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazoneIntracellular Signaling Peptides and ProteinsIron Chelating AgentsIsoniazidN-myc Downstream-Regulated Gene 1 ProteinProto-Oncogene Proteins c-mdm2ThiosemicarbazonesTP63 protein, humanTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor ProteinsDFODp44mTMDM2p21CIP1/WAF1p53

Identifiers

PMID26335183
PMCPMC4745756
OpenAlexW1721952849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.